NASDAQ · TECX
Tectonic Therapeutic, Inc.
$20.50-$0.06 (-0.29%)
Tectonic Therapeutic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.14% below the high.
Loading market information…
NASDAQ · BVXV · USD
Stock price, earnings
Quote as of Sep 6, 2023, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
BiondVax Pharmaceuticals Ltd.’s quoted price sits in the lower half of its reported 52-week range, 88.16% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow BiondVax Pharmaceuticals Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BiondVax Pharmaceuticals Ltd. is an Israeli-based biopharmaceutical company currently in its development stage. Its core mission involves the research, production, and market introduction of therapeutic products designed for the prevention and treatment of a range of infectious and other medical conditions. The company has established strategic licensing and collaboration agreements with prominent scientific institutions, notably the Max Planck Society and the University Medical Center Göttingen. These partnerships are geared towards the advancement and commercialization of nanosized antibodies (NanoAbs), including a specific candidate for COVID-19, and extending this technology to address various other disease indications. Founded in 2003, BiondVax maintains its corporate headquarters in Jerusalem, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:01 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$20.50-$0.06 (-0.29%)
Tectonic Therapeutic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.14% below the high.
$3.06-$0.30 (-8.93%)
Neuphoria Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.67% below the high.
$5.20+$1.69 (+48.15%)
TNF Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.33% below the high.
$0.11$0.00 (0.0%)
Tricida, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.22% below the high.
$0.94-$0.01 (-0.53%)
Fresh Tracks Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.44% below the high.
$1.71+$1.71 (+100.0%)
Aptose Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.04% below the high.
$0.03$0.00 (0.0%)
Gamida Cell Ltd.’s quoted price sits in the lower half of its reported 52-week range, 17.22% below the high.
$0.24+$0.01 (+5.66%)
Hillstream BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.06% below the high.
